Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch

Summary

This study will assess efficacy and safety of intraseasonal specific short-term immunotherapy with Depiquick® Birch in patients with allergic rhinitis and or rhinoconjunctivitis with or without intermittent asthma that have a clinical relevant IgE-mediated allergic sensitization against birch pollen. The term "intraseasonal" means that patients will start with immunotherapy treatment during the birch pollen season, i.e. when the already experience allergic symptoms.

Timeline

Start

2012-03

Primary completion

2012-07

Completion

2012-07

Drugs

Indications